Prognostic impact of serum soluble LR11 in newly diagnosed diffuse large B-cell lymphoma: A multicenter prospective analysis.
Prognostic impact of serum soluble LR11 in newly diagnosed diffuse large B-cell lymphoma: A multicenter prospective analysis.
复制标题
血清可溶性 LR11 对新诊断的弥漫性大 B 细胞淋巴瘤的预后影响：多中心前瞻性分析。
DOI：
10.1016/j.cca.2016.10.008
复制
发表时间：
2016
期刊：
影响因子：
--
通讯作者：
Nakaseko C.
中科院分区：
文献类型：
--
作者：
Sugita Y;Ohwada C;Kawaguchi T;Muto T;Tsukamoto S;Takeda Y1;Mimura N;Takeuchi M ;Sakaida E;Shimizu N;Tanaka H;Abe D;Fukazawa M;Sugawara T;Aotsuka N;Nishiwaki K;Shono K;Ebinuma H;Fujimura K;Bujo H;Yokote K;Nakaseko C.
背景LR11(又称SorLA或SORL1)是一种I型膜蛋白，最初被认为是动脉粥样硬化和阿尔茨海默病的生物标志物。我们最近发现LR11在弥漫性大B细胞淋巴瘤(DLBCL)细胞中特异表达，回顾队列中血清sLR11浓度高表明生存率较低。在这项研究中，我们前瞻性地验证了血清sLR11在97例新诊断、未经治疗的DLBCL患者中的临床影响。结果DLBCL患者血清sLR11浓度较正常对照组升高(平均浓度：21.2g±0.06vs.8.8±1.8g ng/ml，P=0.0001)，缓解期显著降低(平均值：17.4g±116.4vs.10.9g±24.5 ng/ml，P=0.02)。血清sLR11浓度升高受肿瘤负荷和骨髓侵袭的影响。SLR11浓度高的患者2-y OS和PFS显著降低(≤为18.1 ng/ml vs.18.1 ng/ml；2-y OS：89.0%vs.56.4%，P<；0.0001；2-y PFS：85.8%vs.56.9%，P<；0.0001)。结论血清sLR11是一种预测初诊DLBCL患者生存的肿瘤标志物。
BackgroundLR11 (also called SorLA or SORL1) is a type I membrane protein, originally identified as a biomarker for atherosclerosis and Alzheimer's disease. We recently found that LR11 was specifically expressed in Diffuse Large B-cell lymphoma (DLBCL) cells, and high serum sLR11 concentrations in retrospective cohort indicated inferior survival. In this study, we prospectively validated the clinical impact of serum sLR11 in 97 patients with newly-diagnosed, untreated DLBCL.ResultsSerum sLR11 concentrations were increased in DLBCL patients compared to normal controls (mean ± SD: 21.2 ± 27.6 vs. 8.8 ± 1.8 ng/ml,P< 0.0001), and significantly reduced at remission (mean ± SD: 17.4 ± 16.4 vs. 10.9 ± 4.5 ng/ml,P= 0.02). Increased serum sLR11 concentrations were affected by tumor burden and bone marrow invasion. The 2-y OS and PFS were significantly lower in patients with high sLR11 concentrations (≤ 18.1 ng/ml vs. > 18.1 ng/ml; 2-y OS: 89.0% vs. 56.4%,P< 0.0001; 2-y PFS: 85.8% vs. 56.9%,P< 0.0001).ConclusionsSerum sLR11 is a tumor-derived biomarker for predicting the survival of newly diagnosed patients with DLBCL.
登录
查看更多内容
影响因子：
3.7
作者：
Ohyashiki K;Umezu T;Yoshizawa S;Ito Y;Ohyashiki M;Kawashima H;Tanaka M;Kuroda M;Ohyashiki JH
通讯作者：
Ohyashiki JH
非霍奇金淋巴瘤预后因素的最佳利用。
DOI：
--
发表时间：
2006
期刊：
Hematology. American Society of Hematology. Education Program
影响因子：
--
作者：
L. Sehn
通讯作者：
L. Sehn
影响因子：
3.1
作者：
Kim, Seok Jin;Lee, Seung Jin;Kim, Byung Soo
通讯作者：
Kim, Byung Soo
影响因子：
2.1
作者：
Choi, Yong Won;Ahn, Mi Sun;Sheen, Seung Soo
通讯作者：
Sheen, Seung Soo
影响因子：
20.3
作者：
Hans, CP;Weisenburger, DD;Chan, WC
通讯作者：
Chan, WC